, Aug. 31, 2012
/PRNewswire/ - DiagnoCure Inc. (TSX: CUR), a
life sciences company that develops and commercializes
high-value cancer diagnostic tests, announced today that the Company
will release its third quarter results on September 6, 2012
, at about 4
At 4:30 p.m. (EDT)
the same day, management will hold a conference
call with investors to discuss these results.
Investors and financial analysts wishing to participate in the
"DiagnoCure Q3 2012 Earnings Announcement" conference call shall dial
the toll-free number 1-888-231-8191, and provide the conference ID
The event will also be webcasted live on DiagnoCure's website at www.diagnocure.com, through the hyperlink under the "Presentations" page of the
"Investors" tab. A replay of the audio conference will be available on
September 10, 2012.
DiagnoCure (TSX: CUR) is a life sciences company that develops and
commercializes high-value cancer diagnostic tests that increase
clinician and patient confidence in making critical treatment
decisions. In 2008, the Company launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and
granted the worldwide exclusive rights to this test to Signal Genetics
in June 2011. The Company has also granted a worldwide exclusive
license agreement to Gen-Probe, now a wholly-owned subsidiary of
Hologic Inc. (HOLX:NASDAQ) operating as Hologic Gen-Probe, for the
development and commercialization of a third-generation prostate cancer
test using PCA3, DiagnoCure's proprietary molecular biomarker.
Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE
mark and is approved for commercialization in Canada and the United
States. For more information, visit www.diagnocure.com.
This release contains forwardlooking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forwardlooking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forwardlooking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forwardlooking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE DIAGNOCURE INC.